[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 55, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 56, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient Advocacy & External Affairs Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.24, "open": 3.24, "dayLow": 3.14, "dayHigh": 3.29, "regularMarketPreviousClose": 3.24, "regularMarketOpen": 3.24, "regularMarketDayLow": 3.14, "regularMarketDayHigh": 3.29, "beta": 0.348, "forwardPE": -6.7340426, "volume": 1107603, "regularMarketVolume": 1107603, "averageVolume": 2487918, "averageVolume10days": 1863970, "averageDailyVolume10Day": 1863970, "bid": 3.15, "ask": 3.24, "bidSize": 500, "askSize": 100, "marketCap": 591911936, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 3.89, "priceToSalesTrailing12Months": 38.30897, "fiftyDayAverage": 2.7075, "twoHundredDayAverage": 2.295935, "currency": "USD", "enterpriseValue": 398581952, "floatShares": 109117683, "sharesOutstanding": 187018000, "sharesShort": 16908440, "sharesShortPriorMonth": 16985594, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0904, "heldPercentInsiders": 0.18466, "heldPercentInstitutions": 0.71226996, "shortRatio": 9.41, "shortPercentOfFloat": 0.123100005, "bookValue": 0.401, "priceToBook": 7.892768, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -111566000, "trailingEps": -0.78, "forwardEps": -0.47, "enterpriseToRevenue": 25.797, "enterpriseToEbitda": -5.694, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.165, "targetHighPrice": 9.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.95, "targetMedianPrice": 7.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 143940000, "totalCashPerShare": 0.77, "ebitda": -70003000, "totalDebt": 61885000, "quickRatio": 3.916, "currentRatio": 4.077, "totalRevenue": 15451000, "debtToEquity": 82.583, "revenuePerShare": 0.133, "returnOnAssets": -0.29838, "returnOnEquity": -2.94036, "freeCashflow": -68508496, "operatingCashflow": -73018000, "revenueGrowth": 0.44, "grossMargins": 1.0, "operatingMargins": -4.38319, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-28"}]